Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers

European Journal of Dermatology

Volumn 23, Issue 2, 2013, Pages 218-223

  Eichner, Saskia ^a   Thoma Uszynski, Sybille ^a   Herrgott, Ilka ^a   Sebald, Heidi ^b   Debus, Andrea ^b   Tsianakas, Athanasios ^a,c   Ehrchen, Jan ^a,c   Harms, Gundel ^c   Simon, Miklos ^a   Sunderkötter, Cord ^a,c   Bogdan, Christian ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; C REACTIVE PROTEIN; MILTEFOSINE;

ADULT; AGED; ARTICLE; BOLIVIA; CASE REPORT; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOGRAPHY; ERYTHEMA; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LEISHMANIA BRAZILIENSIS; LEISHMANIA BRAZILIENSIS INFECTION; LEISHMANIASIS; LYMPHADENITIS; LYMPHADENOPATHY; LYMPHOCYTE; MALE; NEUTROPHIL COUNT; PARAGUAY; PERU; PHENOTYPE; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCAR FORMATION; SKIN BIOPSY; SKIN DEFECT; SKIN LEISHMANIASIS; SKIN ULCER; TRAVEL; WOUND HEALING;

CUTANEOUS LEISHMANIASIS; LEISHMANIA (V.) BRAZILIENSIS; MUCOSAL LEISHMANIASIS;

ADULT; AGED; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MALE; PHOSPHORYLCHOLINE; SOUTH AMERICA; TRAVEL; YOUNG ADULT;

EID: 84877761262     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.1934     Document Type: Article

References (55)

1. C. Leishmaniasis in Rheumatology, Hematology, and Oncology: Epidemiological, Immunological, and Clinical Aspects and Caveats. Ann. Rheumatic Diseases 2012; 71(SUPPL. 2): i60-i66
2. Garcia AL, Parrado R, Rojas E, Delgado R, Dujardin JC, Reithinger R. Leishmaniases in Bolivia: comprehensive review and current status. Am J Trop Med Hyg 2009; 80: 704-711
3. Grimaldi G Jr., Tesh RB. Leishmaniases of the New World: current concepts and implications for future research. Clin Microbiol Rev 1993; 6: 230-250
4. Weigle K, Saravia NG. Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous leishmaniasis. Clin. Dermatol 1996; 14: 433-450
5. Silveira FT, Lainson R, De Castro Gomes CM, Laurenti MD, Corbett CE. Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis. Parasite Immunol 2009; 31: 423-431
6. Boecken G, Sunderkotter C, Bogdan C, et al. Diagnosis and therapy of cutaneous and mucocutaneous Leishmaniasis in Germany. J Dtsch Dermatol Ges 2011; 9 SUPPL.8: 1-51
7. Bogdan C, Schönian G, Banuls A-L, et al. Visceral leishmaniosis in a German child that had never entered a known endemic area: case report and review of the literature. Clin Infect Dis 2001; 32: 302-307
8. Schulz A, Mellenthin K, Schonian G, Fleischer B, Drosten C. Detection, differentiation, and quantitation of pathogenic leishmania organisms by a fluorescence resonance energy transfer-based real-time PCR assay. J Clin Microbiol 2003; 41: 1529-1535
9. Marfurt J, Niederwieser I, Makia ND, Beck HP, Felger I. Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP. Diagn Microbiol Infect Dis 2003; 46: 115-124
10. Montalvo AM, Fraga J, Monzote L, et al. Heat-shock protein 70 PCR-RFLP: a universal simple tool for Leishmania species discrimination in the New and Old World. Parasitology 2010; 137: 1159-1168
11. Lucas CM, Franke ED, Cachay MI, et al. Geographic distribution and clinical description of leishmaniasis cases in Peru. Am J Trop Med Hyg 1998; 59: 312-317
12. Yadon ZE, Rodrigues LC, Davies CR, Quigley MA. Indoor and peridomestic transmission of American cutaneous leishmaniasis in northwestern Argentina: a retrospective case-control study. Am J Trop Med Hyg 2003; 68: 519-526
13. Salomon OD, Acardi SA, Liotta DJ, et al. Epidemiological aspects of cutaneous leishmaniasis in the Iguazu falls area of Argentina. Acta Trop 2009; 109: 5-11
14. Salomon OD, Mocarbel NJ, Pedroni E, Colombo J, Sandillu M. [Phlebotominae: vectors of leishmaniasis in the provinces of Santa Fe and Entre Rios, Argentina]. Medicina (B Aires) 2006; 66: 220-224
15. Hashiguchi Y, Arias O, Maciel D, Mansur J, Furuya M, Kawabata M. Cutaneous leishmaniasis in south-eastern Paraguay: a study of an endemic area at Limoy. Trans R Soc Trop Med Hyg 1991; 85: 592-4
16. Sousa AQ, Parise ME, Pompeu MM, et al. Bubonic leishmaniasis: a common manifestation of Leishmania (Viannia) braziliensis infection in Ceara, Brazil. Am J Trop Med Hyg 1995; 53: 380-385
17. Barral A, Guerreiro J, Bomfim G, Correia D, Barral-Netto M, Carvalho EM. Lymphadenopathy as the first sign of human cutaneous infection by Leishmania braziliensis. Am J Trop Med Hyg 1995; 53: 256-259
18. Harms G, Fraga F, Batroff B, Oliveira F, Feldmeier H. Cutaneous leishmaniasis associated with extensive lymphadenopathy during an epidemic in Ceara State, northeast Brazil. Acta Trop 2005; 93: 303-310
19. Bomfim G, Andrade BB, Santos S, Clarencio J, Barral-Netto M, Barral A. Cellular analysis of cutaneous leishmaniasis lymphadenopathy: insights into the early phases of human disease. Am J Trop Med Hyg 2007; 77: 854-859
20. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by IL-10. J Exp Med 1991; 174: 1549-1555
21. Azadeh B. "Localized" leishmania lymphadenitis: a light and electron microscopic study. Am J Trop Med Hyg 1985; 34: 447-455
22. Gaafar A, Ismail A, el Kadaro AY, Hashim E, Khalil EA, el Hassan A. Necrotizing and suppurative lymphadenitis in Leishmania major infections. Trop Med Int Health 1996; 1: 243-250
23. Ignatius R, Loddenkemper C, Woitzik J, Schneider T, Harms G. Localized leishmanial lymphadenopathy: an unusual manifestation of leishmaniasis in a traveler in southern Europe. Vector Borne Zoonotic Dis 2011; 11: 1213-1215
24. Marsden PD, Badaro R, Netto EM, Casler JD. Spontaneous clinical resolution without specific treatment in mucosal leishmaniasis. Trans R Soc Trop Med Hyg 1991; 85: 221
25. Mahdi M, Elamin EM, Melville SE, et al. Sudanese mucosal leishmaniasis: isolation of a parasite within the Leishmania donovani complex that differs genotypically from L. donovani causing classical visceral leishmaniasis. Infect Genet Evol 2005; 5: 29-33
26. Sethuraman G, Sharma VK, Salotra P. Indian mucosal leishmaniasis due to Leishmania donovani infection. N Engl J Med 2008; 358: 313-315
27. Benmously-Mlika R, Fenniche S, Kerkeni N, Aoun K, Khedim A, Mokhtar I. [Primary Leishmania infantum MON-80 endonasal leishmaniasis in Tunisia]. Ann Dermatol Venereol 2008; 135: 389-392
28. Richter J, Hanus I, Haussinger D, Loscher T, Harms G. Mucosal Leishmania infantum infection. Parasitol Res 2011; 109: 959-62
29. Daneshbod Y, Oryan A, Davarmanesh M, et al. Clinical, histopathologic, and cytologic diagnosis of mucosal leishmaniasis and literature review. Arch Pathol Lab Med 2011; 135: 478-482
30. Weigle KA, Saravia NG, de Davalos M, Moreno LH, D'Alessandro A. Leishmania braziliensis from the Pacific coast region of Colombia: foci of transmission, clinical spectrum and isoenzyme phenotypes. Am J Trop Med Hyg 1986; 35: 722-731
31. Klotz O, Lindenberg H. The pathology of leishmaniosis of the nose. Am J Trop Med Hyg 1923; s1-S3: 117-141
32. Jones TC, Johnson WD Jr., Barretto AC, et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis 1987; 156: 73-83
33. Osorio LE, Castillo CM, Ochoa MT. Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: clinical characteristics. Am J Trop Med Hyg 1998; 59: 49-52
34. Boaventura VS, Cafe V, Costa J, et al. Concomitant early mucosal and cutaneous leishmaniasis in Brazil. Am J Trop Med Hyg 2006; 75: 267-269
35. Tuon FF, Amato VS, Graf ME, Siqueira AM, Nicodemo AC, Amato Neto V. Treatment of New World cutaneous leishmaniasis-a systematic review with a meta-analysis. Int J Dermatol 2008; 47: 109-124
36. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009:CD004834
37. Zaghi D, Panosian C, Gutierrez MA, Gregson A, Taylor E, Ochoa MT. NewWorld cutaneous leishmaniasis: current challenges in diagnosis and parenteral treatment. J Am Acad Dermatol 2011; 64: 587-592
38. Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38: 1266-1272
39. Soto J, Berman J. Treatment of New World cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 2006; 100 Suppl 1: S34-S40
40. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44: 350-356
41. Velez I, Lopez L, Sanchez X, Mestra L, Rojas C, Rodriguez E. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83: 351-356
42. Machado PR, Ampuero J, Guimaraes LH, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2011; 4: e912
43. WHO. Control of Leishmaniasis. WHO Technical Report Series 2010; 949: 1-187
44. Yardley V, Croft SL, De Doncker S, et al. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 2005; 73: 272-275
45. Sanchez-Canete MP, Carvalho L, Perez-Victoria FJ, Gamarro F, Castanys S. Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob Agents Chemother 2009; 53: 1305-1313
46. Brown M, Noursadeghi M, Boyle J, Davidson RN. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol 2005; 153: 203-205
47. Campos-Munoz L, Quesada-Cortes A, Martin-Diaz MA, Rubio- Flores C, de Lucas-Laguna R. Leishmania braziliensis: report of a pediatric imported case with response to liposomal amphotericin B. Actas Dermosifiliogr 2007; 98: 42-44
48. Ramanathan R, Talaat KR, Fedorko DP, Mahanty S, Nash TE. A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis. Am J Trop Med Hyg 2011; 84: 109-117
49. Harms G, Scherbaum H, Reiter-Owona I, Stich A, Richter J. Treatment of imported NewWorld cutaneous leishmaniasis in Germany. Int J Dermatol 2011; 50: 1336-1342
50. Solomon M, Baum S, Barzilai A, Scope A, Trau H, Schwartz E. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol 2007; 56: 612-616
51. Wortmann G, Zapor M, Ressner R, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83: 1028-1033
52. Guimaraes LH, Machado PR, Lago EL, et al. Atypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia. Brazil. Trans R Soc Trop Med Hyg 2009; 103: 712-715
53. Amato VS, Tuon FF, Imamura R, Abegao de Camargo R, Duarte MI, Neto VA. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. J Eur Acad Dermatol Venereol 2009; 23: 1026-1034
54. Weitzel T, Mühlberger N, Jelinek T, et al. Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network. Eur J Clin Microbiol Infect Dis 2005; 24: 471-476
55. Harms-Zwingenberger G, Bienzle U. Leishmaniasis in Germany. Dtsch Artzebl 2007; 104: A3108-A3113.